Display options
Cite
Evans BD, Chapman P, Dady P, et al. Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer. Int J Gynecol Cancer. 1994;4(1):66-71doi: 10.1046/j.1525-1438.1994.04010066.x.
Evans, B. D., Chapman, P., Dady, P., Forgeson, G., Perez, D., McKeage, M., & Mitchell, P. (1994). Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 4(1), 66-71. https://doi.org/10.1046/j.1525-1438.1994.04010066.x
Evans, B.D., et al. "Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 4,1 (1994): 66-71. doi: https://doi.org/10.1046/j.1525-1438.1994.04010066.x
Evans BD, Chapman P, Dady P, Forgeson G, Perez D, McKeage M, Mitchell P. Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer. Int J Gynecol Cancer. 1994 Jan;4(1):66-71. doi: 10.1046/j.1525-1438.1994.04010066.x. PMID: 11578387.
Copy Download .nbib Format: NLM
Share it on

Int J Gynecol Cancer. 1994 Jan;4(1):66-71. doi: 10.1046/j.1525-1438.1994.04010066.x.

Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

B.D. Evans, P. Chapman, P. Dady, G. Forgeson, D. Perez, M. McKeage, P. Mitchell

Affiliations

  1. Oncology Unit, Palmerston North Hospital, Palmerson North; Oncology Unit, Waikato Hospital, Hamilton; Oncology Unit, Wellington Hospital, Wellington; Oncology Unit, Dunedin Hospital, Dunedin; and Oncology Unit, Auckland Hospital, Auckland, New Zealand.

PMID: 11578387 DOI: 10.1046/j.1525-1438.1994.04010066.x

Abstract

Fifty-six patients with ovarian cancer (three stage IC, nine stage II, 33 stage III and II stage IV) were treated with carboplatin 350 mg m-2 i.v. day 1 and chlorambucil orally 0.15 mg kgm-1 days 1-7 inclusive, repeated every 28 days for eight courses. The regimen was well tolerated and was virtually free of nephro- and neurotoxicity. Grade III or IV hematology toxicity occurred in 18 patients but only 31 or 330 courses administered were delayed. Of 40 assessable patients eight achieved a clinical/radiologic complete response and 17 a clinical/radiologic partial response. Actuarial survival at 50 months was 65% for stage II patients, 27% for stage III patients and no stage IV patients survived beyond 20 months. Forty-two per cent of patients with residual disease less 2 cm survived 50 months, compared with 44% of patients with moderate volume (2-5 cm) residual disease and 6% of patients with bulk residual disease. This is an active, well tolerated regimen. However, only patients with small volume residual disease have a significant chance of prolonged survival.

Publication Types